HIF prolyl hydroxylase inhibitors for the treatment of renal anaemia and beyond

Nature Reviews Nephrology

Volumn 12, Issue 3, 2016, Pages 157-168

  Maxwell, Patrick H ^a   Eckardt, Kai Uwe ^b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; HYPOXIA INDUCIBLE FACTOR 2ALPHA; HYPOXIA INDUCIBLE FACTOR PROLYL HYDROXYLASE INHIBITOR; PHD2 PROTEIN; PROTEIN; UNCLASSIFIED DRUG; HYPOXIA INDUCIBLE FACTOR PROLINE DIOXYGENASE;

ANEMIA; ARTICLE; CLINICAL TRIAL (TOPIC); CONTROLLED CLINICAL TRIAL (TOPIC); DRUG EFFECT; DRUG INDICATION; DRUG POTENCY; ERYTHROPOIESIS; GENE ACTIVATION; GENE TARGETING; HUMAN; KIDNEY DISEASE; KIDNEY POLYCYSTIC DISEASE; LIVER; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLEIOTROPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL ANEMIA; ANTAGONISTS AND INHIBITORS; CHRONIC KIDNEY FAILURE; COMPLICATION;

ANEMIA; ERYTHROPOIETIN; HUMANS; HYPOXIA-INDUCIBLE FACTOR-PROLINE DIOXYGENASES; RENAL INSUFFICIENCY, CHRONIC;

EID: 84958920828     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2015.193     Document Type: Article

References (146)

1. Semenza, G. L. Oxygen sensing, hypoxia-inducible factors, and disease pathophysiology. Annu. Rev. Pathol. 9, 47-71 (2014
2. Chowdhury, R., et al. Selective small molecule probes for the hypoxia inducible factor (HIF) prolyl hydroxylases. ACS Chem. Biol. 8, 1488-1496 (2013
3. Rabinowitz, M. H. Inhibition of hypoxia-inducible factor prolyl hydroxylase domain oxygen sensors: tricking the body into mounting orchestrated survival and repair responses. J. Med. Chem. 56, 9369-9402 (2013
4. Macdougall, I. C., & Obrador, G. T. How important is transfusion avoidance in 2013? Nephrol. Dial. Transplant. 28, 1092-1099 (2013
5. Winearls, C. G., et al. Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet 2, 1175-1178 (1986
6. Palmer, S. C., et al. Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-Analysis. Cochrane Database Syst. Rev. 12, CD010590 (2014
7. Palmer, S. C., Saglimbene, V., Craig, J. C., Navaneethan, S. D., & Strippoli, G. F. Darbepoetin for the anaemia of chronic kidney disease. Cochrane Database Syst. Rev. 3, CD009297 (2014
8. Macdougall, I. C., et al. Peginesatide for anemia in patients with chronic kidney disease not receiving dialysis. N. Engl. J. Med. 368, 320-332 (2013
9. Fishbane, S., et al. Peginesatide in patients with anemia undergoing hemodialysis. N. Engl. J. Med. 368, 307-319 (2013
10. Macdougall, I. C., et al. A peptide-based erythropoietin-receptor agonist for pure red-cell aplasia. N. Engl. J. Med. 361, 1848-1855 (2009
11. Kaushik, T., & Yaqoob, M. M. Lessons learned from peginesatide in the treatment of anemia associated with chronic kidney disease in patients on dialysis. Biologics 7, 243-246 (2013
12. Eckardt, K. U. Anaemia: the safety and efficacy of peginesatide in patients with CKD. Nat. Rev. Nephrol. 9, 192-193 (2013
13. Babitt, J. L., & Lin, H. Y. Mechanisms of anemia in CKD. J. Am. Soc. Nephrol. 23, 1631-1634 (2012
14. Rossert, J., Casadevall, N., & Eckardt, K. U. Anti-erythropoietin antibodies and pure red cell aplasia. J. Am. Soc. Nephrol. 15, 398-406 (2004
15. Macdougall, I. C., et al. Incidence of erythropoietin antibody-mediated pure red cell aplasia: the Prospective Immunogenicity Surveillance Registry (PRIMS). Nephrol. Dial. Transplant. 30, 451-460 (2015
16. Pfeffer, M. A., et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N. Engl. J. Med. 361, 2019-2032 (2009
17. Singh, A. K., et al. Correction of anemia with epoetin alfa in chronic kidney disease. N. Engl. J. Med. 355, 2085-2098 (2006
18. Zarychanski, R., & Houston, D. S. Anemia of chronic disease: a harmful disorder or an adaptive, beneficial response? CMAJ 179, 333-337 (2008
19. Manns, B. J., & Tonelli, M. The new FDA labeling for ESA-implications for patients and providers. Clin. J. Am. Soc. Nephrol. 7, 348-353 (2012
20. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int. Suppl. 2, 279-335 (2012
21. Epstein, A. C., et al. C. elegans EGL 9 and mammalian homologues define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107, 43-54 (2001
22. Laitala, A., et al. Transmembrane prolyl 4 hydroxylase is a fourth prolyl 4 hydroxylase regulating EPO production and erythropoiesis. Blood 120, 3336-3344 (2012
23. Rose, N. R., McDonough, M. A., King, O. N., Kawamura, A., & Schofield, C. J. Inhibition of 2 oxoglutarate dependent oxygenases. Chem. Soc. Rev. 40, 4364-4397 (2011
24. Johansson, C., et al. The roles of Jumonji-Type oxygenases in human disease. Epigenomics 6, 89-120 (2014
25. Feng, T., et al. Optimal translational termination requires C4 lysyl hydroxylation of eRF1. Mol. Cell 53, 645-654 (2014
26. Singleton, R. S., et al. OGFOD1 catalyzes prolyl hydroxylation of RPS23 and is involved in translation control and stress granule formation. Proc. Natl Acad. Sci. USA 111, 4031-4036 (2014
27. Walport, L. J., et al. Human UTY(KDM6C) is a male-specific N? methyl lysyl demethylase. J. Biol. Chem. 289, 18302-18313 (2014
28. Liu, L., et al. Hairless is a histone H3K9 demethylase. FASEB J. 28, 1534-1542 (2014
29. Watanabe, S., et al. JMJD1C demethylates MDC1 to regulate the RNF8 and BRCA1 mediated chromatin response to DNA breaks. Nat. Struct. Mol. Biol. 20, 1425-1433 (2013
30. Masson, N., Willam, C., Maxwell, P. H., Pugh, C. W., & Ratcliffe, P. J. Independent function of two destruction domains in hypoxia-inducible factor α chains activated by prolyl hydroxylation. EMBO J. 20, 5197-5206 (2001
31. Hirsila, M., Koivunen, P., Gunzler, V., Kivirikko, K. I., & Myllyharju, J. Characterization of the human prolyl 4 hydroxylases that modify the hypoxia-inducible factor. J. Biol. Chem. 278, 30772-30780 (2003
32. Lando, D., et al. FIH 1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes Dev. 16, 1466-1471 (2002
33. Schodel, J., et al. High-resolution genome-wide mapping of HIF-binding sites by ChIP-seq. Blood 117, e207-e217 (2011
34. Scholz, C. C., et al. Regulation of IL 1β induced NF ?B by hydroxylases links key hypoxic and inflammatory signaling pathways. Proc. Natl Acad. Sci. USA 110, 18490-18495 (2013
35. Coleman, M. L., et al. Asparaginyl hydroxylation of the Notch ankyrin repeat domain by factor inhibiting hypoxia-inducible factor. J. Biol. Chem. 282, 24027-24038 (2007
36. Yang, M., et al. Asparagine and aspartate hydroxylation of the cytoskeletal ankyrin family is catalyzed by factor-inhibiting hypoxia-inducible factor. J. Biol. Chem. 286, 7648-7660 (2011
37. Maxwell, P. H., et al. Identification of the renal erythropoietin-producing cells using transgenic mice. Kidney Int. 44, 1149-1162 (1993
38. Bachmann, S., Le Hir, M., & Eckardt, K. U. Co localization of erythropoietin messenger RNA and ecto 5?-nucleotidase immunoreactivity in peritubular cells of rat renal cortex indicates that fibroblasts produce erythropoietin. J. Histochem. Cytochem. 41, 335-341 (1993
39. Obara, N., et al. Repression via the GATA box is essential for tissue-specific erythropoietin gene expression. Blood 111, 5223-5232 (2008
40. Rosenberger, C., et al. Expression of hypoxia-inducible factor 1α and-2α in hypoxic and ischemic rat kidneys. J. Am. Soc. Nephrol. 13, 1721-1732 (2002
41. Schietke, R. E., et al. Renal tubular HIF 2α expression requires VHL inactivation and causes fibrosis and cysts. PLoS ONE 7, e31034 (2012
42. Scortegagna, M., et al. HIF 2α regulates murine hematopoietic development in an erythropoietin-dependent manner. Blood 105, 3133-3140 (2005
43. Percy, M. J., et al. A gain of function mutation in the HIF2A gene in familial erythrocytosis. N. Engl. J. Med. 358, 162-168 (2008
44. Gale, D. P., Harten, S. K., Reid, C. D., Tuddenham, E. G., & Maxwell, P. H. Autosomal dominant erythrocytosis and pulmonary arterial hypertension associated with an activating HIF2α mutation. Blood 112, 919-921 (2008
45. Beall, C. M., et al. Natural selection on EPAS1 (HIF2α) associated with low hemoglobin concentration in Tibetan highlanders. Proc. Natl Acad. Sci. USA 107, 11459-11464 (2010
46. Yi, X., et al. Sequencing of 50 human exomes reveals adaptation to high altitude. Science 329, 75-78 (2010
47. Berra, E., et al. HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF 1α in normoxia. EMBO J. 22, 4082-4090 (2003
48. Appelhoff, R. J., et al. Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor. J. Biol. Chem. 279, 38458-38465 (2004
49. Percy, M. J., et al. A family with erythrocytosis establishes a role for prolyl hydroxylase domain protein 2 in oxygen homeostasis. Proc. Natl Acad. Sci. USA 103, 654-659 (2006
50. Zhang, N., et al. The asparaginyl hydroxylase factor inhibiting HIF 1α is an essential regulator of metabolism. Cell. Metab. 11, 364-378 (2010
51. Takeda, K., et al. Placental but not heart defect is associated with elevated HIFα levels in mice lacking prolyl hydroxylase domain protein 2. Mol. Cell. Biol. 26, 8336-8346 (2006
52. Cunliffe, C. J., Franklin, T. J., Hales, N. J., & Hill, G. B. Novel inhibitors of prolyl 4 hydroxylase. 3. Inhibition by the substrate analogue N oxaloglycine and its derivatives. J. Med. Chem. 35, 2652-2658 (1992
53. Majamaa, K., Gunzler, V., Hanauske-Abel, H. M., Myllyla, R., & Kivirikko, K. I. Partial identity of the 2 oxoglutarate and ascorbate binding sites of prolyl 4 hydroxylase. J. Biol. Chem. 261, 7819-7823 (1986
54. Jaakkola, P., et al. Targeting of HIF α to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292, 468-472 (2001
55. Ivan, M., et al. Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor. Proc. Natl Acad. Sci. USA 99, 13459-13464 (2002
56. Hsieh, M. M., et al. HIF prolyl hydroxylase inhibition results in endogenous erythropoietin induction, erythrocytosis, and modest fetal hemoglobin expression in rhesus macaques. Blood 110, 2140-2147 (2007
57. Flamme, I., et al. Mimicking hypoxia to treat anemia: HIF-stabilizer BAY 85-3934 (molidustat) stimulates erythropoietin production without hypertensive effects. PLoS ONE 9, e111838 (2014
58. Maxwell, P. H., Ferguson, D. J., Nicholls, L. G., Johnson, M. H., & Ratcliffe, P. J. The interstitial response to renal injury: fibroblast-like cells show phenotypic changes and have reduced potential for erythropoietin gene expression. Kidney Int. 52, 715-724 (1997
59. Souma, T., et al. Plasticity of renal erythropoietin-producing cells governs fibrosis. J. Am. Soc. Nephrol. 24, 1599-1616 (2013
60. Chiang, C. K., Tanaka, T., Inagi, R., Fujita, T., & Nangaku, M. Indoxyl sulfate, a representative uremic toxin, suppresses erythropoietin production in a HIF-dependent manner. Lab. Invest. 91, 1564-1571 (2011
61. Wu, I. W., et al. Oral adsorbent AST 120 potentiates the effect of erythropoietin-stimulating agents on stage 5 chronic kidney disease patients: a randomized crossover study. Nephrol. Dial. Transplant. 29, 1719-1727 (2014
62. Blumberg, A., Keller, H., & Marti, H. R. Effect of altitude on erythropoiesis and oxygen affinity in anaemic patients on maintenance dialysis. Eur. J. Clin. Invest. 3, 93-97 (1973
63. Chandra, M., Clemons, G. K., & McVicar, M. I. Relation of serum erythropoietin levels to renal excretory function: evidence for lowered set point for erythropoietin production in chronic renal failure. J. Pediatr. 113, 1015-1021 (1988
64. Walle, A. J., Wong, G. Y., Clemons, G. K., Garcia, J. F., & Niedermayer, W. Erythropoietin-hematocrit feedback circuit in the anemia of end-stage renal disease. Kidney Int. 31, 1205-1209 (1987
65. Brookhart, M. A., et al. The effect of altitude on dosing and response to erythropoietin in ESRD. J. Am. Soc. Nephrol. 19, 1389-1395 (2008
66. Aeberhard, J. M., Schneider, P. A., Vallotton, M. B., Kurtz, A., & Leski, M. Multiple site estimates of erythropoietin and renin in polycythemic kidney transplant patients. Transplantation 50, 613-616 (1990
67. Malyszko, J., Oberbauer, R., & Watschinger, B. Anemia and erythrocytosis in patients after kidney transplantation. Transpl. Int. 25, 1013-1023 (2012
68. Eckardt, K. U., et al. Erythropoietin in polycystic kidneys. J. Clin. Invest. 84, 1160-1166 (1989
69. Shalhoub, R. J., Rajan, U., Goldwasser, E., Karak, J. A., & Antoniou, L. D. Erythrocytosis in patients on long-Term hemodialysis. Ann. Int. Med. 97, 686-690 (1982
70. Bernhardt, W. M., et al. Involvement of hypoxia-inducible transcription factors in polycystic kidney disease. Am. J. Pathol. 170, 830-842 (2007
71. Buchholz, B., et al. Hypoxia-inducible factor 1α causes renal cyst expansion through calcium-Activated chloride secretion. J. Am. Soc. Nephrol. 25, 465-474 (2014
72. Koury, S. T., Bondurant, M. C., Koury, M. J., & Semenza, G. L. Localization of cells producing erythropoietin in murine liver by in situ hybridization. Blood 77, 2497-2503 (1991
73. Maxwell, P. H., et al. Expression of a homologously recombined erythropoietin SV40 T antigen fusion gene in mouse liver: evidence for erythropoietin production by Ito cells. Blood 84, 1823-1830 (1994
74. Eckardt, K. U., Ratcliffe, P. J., Tan, C. C., Bauer, C., & Kurtz, A. Age-dependent expression of the erythropoietin gene in rat liver and kidneys. J. Clin. Invest. 89, 753-760 (1992
75. Kolk-Vegter, A. J., Bosch, E., & van Leeuwen, A. M. Influence of serum hepatitis on haemoglobin level in patients on regular haemodialysis. Lancet 1, 526-528 (1971
76. Naughton, B. A., et al. Hepatic regeneration and erythropoietin production in the rat. Science 196, 301-302 (1977
77. Suzuki, N., et al. Specific contribution of the erythropoietin gene 3? enhancer to hepatic erythropoiesis after late embryonic stages. Mol. Cell. Biol. 31, 3896-3905 (2011
78. Tojo, Y., et al. Hypoxia signaling cascade for erythropoietin production in hepatocytes. Mol. Cell. Biol. 35, 2658-2672 (2015
79. Minamishima, Y. A., & Kaelin, W. G. Jr. Reactivation of hepatic EPO synthesis in mice after PHD loss. Science 329, 407 (2010
80. Weidemann, A., et al. The glial cell response is an essential component of hypoxia-induced erythropoiesis in mice. J. Clin. Invest. 119, 3373-3383 (2009
81. Rankin, E. B., et al. The HIF signaling pathway in osteoblasts directly modulates erythropoiesis through the production of EPO. Cell 149, 63-74 (2012
82. Jelkmann, W. Erythropoietin: structure, control of production, and function. Physiol. Rev. 72, 449-489 (1992
83. Beyer, S., Kristensen, M. M., Jensen, K. S., Johansen, J. V., & Staller, P. The histone demethylases JMJD1A and JMJD2B are transcriptional targets of hypoxia-inducible factor HIF. J. Biol. Chem. 283, 36542-36552 (2008
84. Bhatt, K., et al. MicroRNA 687 induced by hypoxia-inducible factor 1 targets phosphatase and tensin homolog in renal ischemia-reperfusion injury. J. Am. Soc. Nephrol. 26, 1588-1596 (2015
85. Sun, C. C., Vaja, V., Babitt, J. L., & Lin, H. Y. Targeting the hepcidin-ferroportin axis to develop new treatment strategies for anemia of chronic disease and anemia of inflammation. Am. J. Hematol. 87, 392-400 (2012
86. Kim, A., & Nemeth, E. New insights into iron regulation and erythropoiesis. Curr. Opin. Hematol. 22, 199-205 (2015
87. Shah, Y. M., & Xie, L. Hypoxia-inducible factors link iron homeostasis and erythropoiesis. Gastroenterology 146, 630-642 (2014
88. Peyssonnaux, C., et al. Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs). J. Clin. Invest. 117, 1926-1932 (2007
89. Liu, Q., Davidoff, O., Niss, K., & Haase, V. H. Hypoxia-inducible factor regulates hepcidin via erythropoietin-induced erythropoiesis. J. Clin. Invest. 122, 4635-4644 (2012
90. Volke, M., et al. Evidence for a lack of a direct transcriptional suppression of the iron regulatory peptide hepcidin by hypoxia-inducible factors. PLoS ONE 4, e7875 (2009
91. Brigandi, R. A., et al. Induction of erythropoiesis in anemic patients by prolylhydroxylase inhibitor in a repeat dose, randomized placebo controlled trial [poster SA PO117]. J. Am. Soc. Nephrol. 23 (Abstract suppl.), 663A (2012
92. Shalwitz, R., et al. AKB 6548, a new hypoxia-inducible factor prolyl hydroxylase inhibitor, increases hemoglobin in chronic kidney disease patients without increasing basal erythropoietin levels [abstract FR OR116]. J. Am. Soc. Nephrol. 23 (Abstract suppl.), 56A (2012
93. Besarab, A., Szczech, L., Yu, K. H. P., & Neff, T. B. Impact of iron regimen on iron indices and hepcidin during roxadustat anemia correction in incident dialysis patients [poster TH PO847]. J. Am. Soc. Nephrol. 25 (Abstract suppl.), 304A (2014
94. Ashby, D. R., et al. Erythropoietin administration in humans causes a marked and prolonged reduction in circulating hepcidin. Haematologica 95, 505-508 (2010
95. Ashby, D. R., et al. Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease. Kidney Int. 75, 976-981 (2009
96. Gammella, E., et al. Erythropoietins inhibiting impact on hepcidin expression occurs indirectly. Am. J. Physiol. Regul. Integr. Comp. Physiol. 308, R330-R335 (2015
97. Olson, E., et al. Short-Term treatment with a novel HIF-prolyl hydroxylase inhibitor (GSK1278863) failed to improve measures of performance in subjects with claudication-limited peripheral artery disease. Vasc. Med. 19, 473-482 (2014
98. Hill, P., et al. Inhibition of hypoxia inducible factor hydroxylases protects against renal ischemia-reperfusion injury. J. Am. Soc. Nephrol. 19, 39-46 (2008
99. Gossage, L., Eisen, T., & Maher, E. R. VHL, the story of a tumour suppressor gene. Nat. Rev. Cancer 15, 55-64 (2015
100. Gnarra, J. R., et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat. Genet. 7, 85-90 (1994
101. Raval, R. R., et al. Contrasting properties of hypoxia-inducible factor 1 (HIF 1) and HIF 2 in von Hippel-Lindau-Associated renal cell carcinoma. Mol. Cell. Biol. 25, 5675-5686 (2005
102. Mandriota, S. J., et al. HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron. Cancer Cell 1, 459-468 (2002
103. Kondo, K., Kim, W., Lechpammer, M., & Kaelin, W. Inhibition of HIF2α is sufficient to suppress pVHL-defective tumor growth. PLoS Biol. 1, 439-444 (2003
104. Gerlinger, M., et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366, 883-892 (2012
105. Frew, I. J., et al. pVHL and PTEN tumour suppressor proteins cooperatively suppress kidney cyst formation. EMBO J. 27, 1747-1757 (2008
106. Clifford, S. C., et al. Contrasting effects on HIF 1α regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease. Hum. Mol. Genet. 10, 1029-1038 (2001
107. Jochmanova, I., Zelinka, T., Widimsky, J. Jr & Pacak, K. HIF signaling pathway in pheochromocytoma and other neuroendocrine tumors. Physiol. Res. 63, S251-S262 (2014
108. Yang, C., et al. Germ-line PHD1 and PHD2 mutations detected in patients with pheochromocytoma/paraganglioma-polycythemia. J. Mol. Med. (Berl.) 93, 93-104 (2015
109. Pugh, C. W., & Ratcliffe, P. J. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat. Med. 9, 677-684 (2003
110. Kaelin, W. G. Jr. Cancer and altered metabolism: potential importance of hypoxia-inducible factor and 2 oxoglutarate-dependent dioxygenases. Cold Spring Harb. Symp. Quant. Biol. 76, 335-345 (2011
111. Barriga, E. H., Maxwell, P. H., Reyes, A. E., & Mayor, R. The hypoxia factor Hif 1α controls neural crest chemotaxis and epithelial to mesenchymal transition. J. Cell Biol. 201, 759-776 (2013
112. Esteban, M. A., et al. Regulation of E cadherin expression by VHL and hypoxia-inducible factor. Cancer Res. 66, 3567-3575 (2006
113. Higgins, D. F., et al. Hypoxia promotes fibrogenesis in vivo via HIF 1 stimulation of epithelial-To mesenchymal transition. J. Clin. Invest. 117, 3810-3820 (2007
114. Semenza, G. L. Molecular mechanisms mediating metastasis of hypoxic breast cancer cells. Trends Mol. Med. 18, 534-543 (2012
115. Ang, S. O., et al. Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia. Nat. Genet. 32, 614-621 (2002
116. Percy, M. J., et al. Novel exon 12 mutations in the HIF2A gene associated with erythrocytosis. Blood 111, 5400-5402 (2008
117. Bond, J., et al. Dysregulation of the HIF pathway due to VHL mutation causing severe erythrocytosis and pulmonary arterial hypertension. Blood 117, 3699-3701 (2011
118. Smith, T. G., et al. Mutation of von Hippel-Lindau tumour suppressor and human cardiopulmonary physiology. PLoS Med. 3, e290 (2006
119. Hickey, M. M., et al. The von Hippel-Lindau Chuvash mutation promotes pulmonary hypertension and fibrosis in mice. J. Clin. Invest. 120, 827-839 (2010
120. Gordeuk, V. R., et al. Congenital disorder of oxygen sensing: association of the homozygous Chuvash polycythemia VHL mutation with thrombosis and vascular abnormalities but not tumors. Blood 103, 3924-3932 (2004
121. Imanishi, M., et al. Smooth muscle cell-specific Hif 1α deficiency suppresses angiotensin II induced vascular remodelling in mice. Cardiovasc. Res. 102, 460-468 (2014
122. Parathath, S., et al. Hypoxia is present in murine atherosclerotic plaques and has multiple adverse effects on macrophage lipid metabolism. Circ. Res. 109, 1141-1152 (2011
123. Tanaka, T., et al. Cobalt promotes angiogenesis via hypoxia-inducible factor and protects tubulointerstitium in the remnant kidney model. Lab. Invest. 85, 1292-1307 (2005
124. Tanaka, T., et al. Induction of protective genes by cobalt ameliorates tubulointerstitial injury in the progressive Thy1 nephritis. Kidney Int. 68, 2714-2725 (2005
125. Song, Y. R., et al. Activation of hypoxia-inducible factor attenuates renal injury in rat remnant kidney. Nephrol. Dial. Transplant. 25, 77-85 (2010
126. Kobayashi, H., et al. Myeloid cell-derived hypoxia-inducible factor attenuates inflammation in unilateral ureteral obstruction-induced kidney injury. J. Immunol. 188, 5106-5115 (2012
127. Nordquist, L., et al. Activation of hypoxia-inducible factors prevents diabetic nephropathy. J. Am. Soc. Nephrol. 26, 328-338 (2015
128. Bernhardt, W. M., et al. Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD. J. Am. Soc. Nephrol. 21, 2151-2156 (2010
129. Besarab, A., et al. Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG 4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD CKD) patients. Nephrol. Dial. Transplant. 30, 1665-1673 (2015
130. Besarab, A., et al. Roxadustat (FG 4592): correction of anemia in incident dialysis patients. J. Am. Soc. Nephrol. http://dx.doi.org/10.1681/ASN.2015030241 (2015
131. Boettcher, M. F., Lentini, S., Flamme, I., Kubitza, D., & Wensing, G. First in Man study with BAY 85-3934-A new oral selective HIF PH inhibitor for the treatment of renal anemia [poster TH PO1090]. J. Am. Soc. Nephrol. 24 (Abstract suppl.), 347A (2013
132. Holdstock, L., et al. Four-week studies of oral hypoxia-inducible factor-prolyl hydroxylase inhibitor GSK1278863 for treatment of anemia. J. Am. Soc. Nephrol. http://dx.doi.org/10.1681/ASN.2014111139 (2015
133. McCafferty, K., Forbes, S., Thiemermann, C., & Yaqoob, M. M. The challenge of translating ischemic conditioning from animal models to humans: the role of comorbidities. Dis. Model Mech. 7, 1321-1333 (2014
134. Sheldon, R. A., Lee, C. L., Jiang, X., Knox, R. N., & Ferriero, D. M. Hypoxic preconditioning protection is eliminated in HIF 1α knockout mice subjected to neonatal hypoxia-ischemia. Pediatr. Res. 76, 46-53 (2014
135. Sarkar, K., et al. Hypoxia-inducible factor 1 transcriptional activity in endothelial cells is required for acute phase cardioprotection induced by ischemic preconditioning. Proc. Natl Acad. Sci. USA 109, 10504-10509 (2012
136. Chen, R. L., et al. HIF prolyl hydroxylase inhibition prior to transient focal cerebral ischaemia is neuroprotective in mice. J. Neurochem. 131, 177-189 (2014
137. Vogler, M., et al. Pre-And post-conditional inhibition of prolyl-4 hydroxylase domain enzymes protects the heart from an ischemic insult. Pflugers Arch. 467, 2141-2149 (2015
138. Ong, S. G., et al. HIF 1 reduces ischaemia-reperfusion injury in the heart by targeting the mitochondrial permeability transition pore. Cardiovasc. Res. 104, 24-36 (2014
139. Lijkwan, M. A., et al. Short hairpin RNA gene silencing of prolyl hydroxylase 2 with a minicircle vector improves neovascularization of hindlimb ischemia. Hum. Gene Ther. 25, 41-49 (2014
140. Aragones, J., et al. Deficiency or inhibition of oxygen sensor Phd1 induces hypoxia tolerance by reprogramming basal metabolism. Nat. Genet. 40, 170-180 (2008
141. Matsumoto, M., et al. Induction of renoprotective gene expression by cobalt ameliorates ischemic injury of the kidney in rats. J. Am. Soc. Nephrol. 14, 1825-1832 (2003
142. Bernhardt, W. M., et al. Preconditional activation of hypoxia-inducible factors ameliorates ischemic acute renal failure. J. Am. Soc. Nephrol. 17, 1970-1978 (2006
143. Wang, Z., et al. The protective effect of prolyl-hydroxylase inhibition against renal ischaemia requires application prior to ischaemia but is superior to EPO treatment. Nephrol. Dial. Transplant. 27, 929-936 (2012
144. Bernhardt, W. M., et al. Donor treatment with a PHD-inhibitor activating HIFs prevents graft injury and prolongs survival in an allogenic kidney transplant model. Proc. Natl Acad. Sci. USA 106, 21276-21281 (2009
145. Pearl, R. G. Erythropoietin and organ protection: lessons from negative clinical trials. Crit. Care 18, 526 (2014
146. Nauta, T. D., van Hinsbergh, V. W., & Koolwijk, P. Hypoxic signaling during tissue repair and regenerative medicine. Int. J. Mol. Sci. 15, 19791-19815 (2014